Aethlon Medical (AEMD)

$2.38 -0.02 (-0.83%)
Market Cap 2.43M
Revenue (ttm) 0.00
Net Income (ttm) -13.39M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 9,711
Avg Vol 142,254
Day's Range N/A - N/A
Shares Out 973,000.00
Stochastic %K 5%
Beta 1.60
Analysts Hold
Price Target $9.75

Company Profile

Aethlon Medical, Inc., a medical therapeutic company, engages in developing novel immunotherapeutic devices to treat cancer and viral infections in the United States. It develops Hemopurifier, a clinical-stage immunotherapeutic device intended for applications in cancer, and life-threatening viral infections, and use in organ transplantation. The company was founded in 1984 and is based in San Diego, California.

Industry: Medical Devices
Sector: Healthcare
Phone: 619 941 0360
Fax: 619 941 0361
Address:
11555 Sorrento Valley Road, Suite 203, San Diego, United States
Waffels
Waffels Jan. 28 at 4:39 PM
$AEMD this stock still very cute and one my favorite
0 · Reply
smoothest06
smoothest06 Jan. 27 at 2:20 PM
$AEMD
0 · Reply
ChartChartist
ChartChartist Jan. 25 at 7:50 PM
$AEMD im impatient
0 · Reply
echo_fable
echo_fable Jan. 24 at 2:48 PM
$AEMD 5$ by next week?
0 · Reply
echo_fable
echo_fable Jan. 24 at 2:47 PM
$AEMD
0 · Reply
smoothest06
smoothest06 Jan. 23 at 4:06 PM
$AEMD
0 · Reply
inapick
inapick Jan. 23 at 1:34 PM
$AEMD all this company has ever done is drain its investors of their funds through constant R/S's If i could i would
0 · Reply
TheRealSonic
TheRealSonic Jan. 16 at 11:18 PM
The Hedghog’s list for next week: $OCG $EVTV $AEMD $FRGT $BJDX
0 · Reply
shuffle13
shuffle13 Jan. 16 at 10:31 PM
$AEMD https://www.sec.gov/Archives/edgar/data/882291/000168316826000376/aethlon_424b3.htm
0 · Reply
smoothest06
smoothest06 Jan. 16 at 10:30 PM
$AEMD
0 · Reply
Latest News on AEMD
Aethlon Medical Announces Pricing of a Private Placement and Warrant Inducement, Priced At-The-Market for Aggregate Gross Proceeds of $3.3 Million

Dec 5, 2025, 9:15 AM EST - 2 months ago

Aethlon Medical Announces Pricing of a Private Placement and Warrant Inducement, Priced At-The-Market for Aggregate Gross Proceeds of $3.3 Million

Aethlon Medical Announces Publication of Preclinical Data Showing That the GNA Affinity Resin in the Hemopurifier® Binds to Extracellular Vesicles in Long COVID patient samples and Decreases Inflammatory microRNAs

Dec 2, 2025, 8:01 AM EST - 2 months ago

Aethlon Medical Announces Publication of Preclinical Data Showing That the GNA Affinity Resin in the Hemopurifier® Binds to Extracellular Vesicles in Long COVID patient samples and Decreases Inflammatory microRNAs

Aethlon Medical, Inc. (AEMD) Q2 2026 Earnings Call Transcript

Nov 12, 2025, 6:31 PM EST - 2 months ago

Aethlon Medical, Inc. (AEMD) Q2 2026 Earnings Call Transcript

Aethlon Medical Announces Fiscal Q2 2025 Financial Results and Corporate Update

Nov 12, 2025, 4:15 PM EST - 2 months ago

Aethlon Medical Announces Fiscal Q2 2025 Financial Results and Corporate Update

Aethlon Medical to Release Fiscal Second Quarter Financial Results and Host Conference Call on November 12, 2025

Nov 7, 2025, 8:01 AM EST - 3 months ago

Aethlon Medical to Release Fiscal Second Quarter Financial Results and Host Conference Call on November 12, 2025

Aethlon Medical's Hemopurifier® shows Changes in Extracellular Vesicles, Extracellular MicroRNAs, and T Cell Numbers in Australian Oncology Clinical Trial

Oct 7, 2025, 8:01 AM EDT - 4 months ago

Aethlon Medical's Hemopurifier® shows Changes in Extracellular Vesicles, Extracellular MicroRNAs, and T Cell Numbers in Australian Oncology Clinical Trial

Aethlon Medical Announces Pricing of $4.5 Million Public Offering

Sep 4, 2025, 9:15 AM EDT - 5 months ago

Aethlon Medical Announces Pricing of $4.5 Million Public Offering

Aethlon Medical Announces Issuance of Hemopurifier® Patents for the Treatment of Long COVID and COVID-19-associated Coagulopathy (CAC)

Sep 3, 2025, 8:01 AM EDT - 5 months ago

Aethlon Medical Announces Issuance of Hemopurifier® Patents for the Treatment of Long COVID and COVID-19-associated Coagulopathy (CAC)

Aethlon Medical, Inc. (AEMD) Q1 2026 Earnings Call Transcript

Aug 13, 2025, 8:01 PM EDT - 6 months ago

Aethlon Medical, Inc. (AEMD) Q1 2026 Earnings Call Transcript

Aethlon Medical Announces Financial Results for the Fiscal First Quarter Ended June 30, 2025, and Provides Corporate Update

Aug 13, 2025, 4:15 PM EDT - 6 months ago

Aethlon Medical Announces Financial Results for the Fiscal First Quarter Ended June 30, 2025, and Provides Corporate Update

Aethlon Medical to Release Fiscal First Quarter Financial Results and Host Conference Call on August 13, 2025

Aug 5, 2025, 8:01 AM EDT - 6 months ago

Aethlon Medical to Release Fiscal First Quarter Financial Results and Host Conference Call on August 13, 2025

Aethlon Medical, Inc. Announces Positive Data Safety Monitoring Board Review and Recommendation to Advance to Next Clinical Trial Cohort

Jul 15, 2025, 8:01 AM EDT - 7 months ago

Aethlon Medical, Inc. Announces Positive Data Safety Monitoring Board Review and Recommendation to Advance to Next Clinical Trial Cohort

Aethlon Medical, Inc. (AEMD) Q4 2025 Earnings Call Transcript

Jun 26, 2025, 7:35 PM EDT - 7 months ago

Aethlon Medical, Inc. (AEMD) Q4 2025 Earnings Call Transcript

Aethlon Medical Announces Financial Results for the Fiscal Fourth Quarter Ended March 31, 2025, and Provides Corporate Update

Jun 26, 2025, 4:15 PM EDT - 7 months ago

Aethlon Medical Announces Financial Results for the Fiscal Fourth Quarter Ended March 31, 2025, and Provides Corporate Update

Aethlon Medical to Release Fiscal Fourth Quarter Financial Results and Host Conference Call on June 26, 2025

Jun 20, 2025, 8:01 AM EDT - 8 months ago

Aethlon Medical to Release Fiscal Fourth Quarter Financial Results and Host Conference Call on June 26, 2025

Aethlon Medical Treats Second Patient in Australian Hemopurifier® Cancer Trial

Jun 18, 2025, 8:01 AM EDT - 8 months ago

Aethlon Medical Treats Second Patient in Australian Hemopurifier® Cancer Trial

Aethlon Medical to Present New Pre-Clinical Data at the Keystone Symposium on Long COVID and Other Post-Acute Infection Syndromes

Jun 9, 2025, 8:01 AM EDT - 8 months ago

Aethlon Medical to Present New Pre-Clinical Data at the Keystone Symposium on Long COVID and Other Post-Acute Infection Syndromes

Aethlon Medical Announces Publication of Preclinical Data Showing Ability of the Hemopurifier® to Remove Platelet-Derived Extracellular Vesicles from Plasma

May 14, 2025, 8:01 AM EDT - 9 months ago

Aethlon Medical Announces Publication of Preclinical Data Showing Ability of the Hemopurifier® to Remove Platelet-Derived Extracellular Vesicles from Plasma

Aethlon Medical Publishes Preclinical Data on the Hemopurifier® in Transplant Immunology Journal

Mar 10, 2025, 8:01 AM EDT - 11 months ago

Aethlon Medical Publishes Preclinical Data on the Hemopurifier® in Transplant Immunology Journal

Aethlon Medical to Present at the Emerging Growth Conference on February 19, 2025

Feb 13, 2025, 8:01 AM EST - 1 year ago

Aethlon Medical to Present at the Emerging Growth Conference on February 19, 2025

Aethlon Medical, Inc. (AEMD) Q3 2025 Earnings Call Transcript

Feb 12, 2025, 8:11 PM EST - 1 year ago

Aethlon Medical, Inc. (AEMD) Q3 2025 Earnings Call Transcript

Aethlon Medical Announces Financial Results for the Fiscal Third Quarter Ended December 31, 2024 and Provides Corporate Update

Feb 12, 2025, 4:15 PM EST - 1 year ago

Aethlon Medical Announces Financial Results for the Fiscal Third Quarter Ended December 31, 2024 and Provides Corporate Update

Aethlon Medical to Release Fiscal Third Quarter Financial Results and Host Conference Call on February 12, 2025

Feb 5, 2025, 8:01 AM EST - 1 year ago

Aethlon Medical to Release Fiscal Third Quarter Financial Results and Host Conference Call on February 12, 2025

Aethlon Medical Treats First Patient in Australian Hemopurifier® Cancer Trial

Jan 29, 2025, 8:01 AM EST - 1 year ago

Aethlon Medical Treats First Patient in Australian Hemopurifier® Cancer Trial

Aethlon Medical Provides Update on the Ability of Its Hemopurifier® to Capture H5N1 Bird Flu

Dec 20, 2024, 8:01 AM EST - 1 year ago

Aethlon Medical Provides Update on the Ability of Its Hemopurifier® to Capture H5N1 Bird Flu

Biotech and Medical Tech Stocks Report Significant Updates in the Race for Cancer Treatments as Cancer Rates Rise Globally

Nov 14, 2024, 8:00 AM EST - 1 year ago

Biotech and Medical Tech Stocks Report Significant Updates in the Race for Cancer Treatments as Cancer Rates Rise Globally

Aethlon Medical, Inc. (AEMD) Q2 2025 Earnings Call Transcript

Nov 13, 2024, 7:58 PM EST - 1 year ago

Aethlon Medical, Inc. (AEMD) Q2 2025 Earnings Call Transcript

Aethlon Medical Announces Financial Results for the Fiscal Second Quarter Ended September 30, 2024 and Provides Corporate Update

Nov 13, 2024, 4:15 PM EST - 1 year ago

Aethlon Medical Announces Financial Results for the Fiscal Second Quarter Ended September 30, 2024 and Provides Corporate Update

Innovative Medical Technology Advances with First Patient Enrollments

Nov 12, 2024, 8:00 AM EST - 1 year ago

Innovative Medical Technology Advances with First Patient Enrollments

Aethlon Medical Reaches Key Milestone with Enrollment of the First Patient in (FPI) Its Hemopurifier® Cancer Trial in Australia

Nov 11, 2024, 8:01 AM EST - 1 year ago

Aethlon Medical Reaches Key Milestone with Enrollment of the First Patient in (FPI) Its Hemopurifier® Cancer Trial in Australia

Aethlon Medical to Release Fiscal Second Quarter Financial Results and Host Conference Call on November 13, 2024

Nov 6, 2024, 8:01 AM EST - 1 year ago

Aethlon Medical to Release Fiscal Second Quarter Financial Results and Host Conference Call on November 13, 2024

Aethlon Medical to Participate in the 2024 Maxim Healthcare Virtual Summit

Oct 8, 2024, 8:01 AM EDT - 1 year ago

Aethlon Medical to Participate in the 2024 Maxim Healthcare Virtual Summit

Immunotherapy Clinical Trials - A New Approach to Treating Cancer

Sep 19, 2024, 10:00 AM EDT - 1 year ago

Immunotherapy Clinical Trials - A New Approach to Treating Cancer

Aethlon Receives Ethics Committee Approval for Hemopurifier® Cancer Trial in India

Sep 19, 2024, 8:01 AM EDT - 1 year ago

Aethlon Receives Ethics Committee Approval for Hemopurifier® Cancer Trial in India

Aethlon Medical to Present at Virtual Investor Conferences in September

Sep 17, 2024, 8:01 AM EDT - 1 year ago

Aethlon Medical to Present at Virtual Investor Conferences in September

Innovation Driving Cancer's Solid Tumors Market

Sep 17, 2024, 7:30 AM EDT - 1 year ago

Innovation Driving Cancer's Solid Tumors Market

Aethlon Medical Announces Activation of Royal Adelaide Hospital to Begin Patient Screening and Enrollment in Hemopurifier® Cancer Trial

Sep 16, 2024, 8:01 AM EDT - 1 year ago

Aethlon Medical Announces Activation of Royal Adelaide Hospital to Begin Patient Screening and Enrollment in Hemopurifier® Cancer Trial

Aethlon Medical to Present at the Life Sciences Investor Forum September 19th

Sep 13, 2024, 8:35 AM EDT - 1 year ago

Aethlon Medical to Present at the Life Sciences Investor Forum September 19th

Aethlon Medical Announces Publication of Preclinical Data Showing Ability of the Hemopurifier® to Remove Extracellular Vesicles and microRNAs from Renal Perfusates Following Controlled Oxygenated Rewarming of Discarded Donor Kidneys

Aug 27, 2024, 8:01 AM EDT - 1 year ago

Aethlon Medical Announces Publication of Preclinical Data Showing Ability of the Hemopurifier® to Remove Extracellular Vesicles and microRNAs from Renal Perfusates Following Controlled Oxygenated Rewarming of Discarded Donor Kidneys

Aethlon Medical, Inc. (AEMD) Q1 2025 Earnings Call Transcript

Aug 14, 2024, 6:45 PM EDT - 1 year ago

Aethlon Medical, Inc. (AEMD) Q1 2025 Earnings Call Transcript

Aethlon Medical Announces Financial Results for the Fiscal First Quarter Ended June 30, 2024 and Provides Corporate Update

Aug 14, 2024, 4:15 PM EDT - 1 year ago

Aethlon Medical Announces Financial Results for the Fiscal First Quarter Ended June 30, 2024 and Provides Corporate Update

The Cancer Battle - How Smaller Companies Are Making Big Advancements in Treatments for Solid Tumors

Aug 12, 2024, 9:01 AM EDT - 1 year ago

The Cancer Battle - How Smaller Companies Are Making Big Advancements in Treatments for Solid Tumors

Aethlon Medical Receives Second Ethics Committee Approval for Hemopurifier® Cancer Trial

Aug 12, 2024, 8:01 AM EDT - 1 year ago

Aethlon Medical Receives Second Ethics Committee Approval for Hemopurifier® Cancer Trial

Aethlon Medical to Release Fiscal First Quarter Financial Results and Host Conference Call on August 14, 2024

Aug 6, 2024, 9:12 AM EDT - 1 year ago

Aethlon Medical to Release Fiscal First Quarter Financial Results and Host Conference Call on August 14, 2024

Aethlon Medical, Inc. (AEMD) Q4 2024 Earnings Call Transcript

Jun 27, 2024, 6:37 PM EDT - 1 year ago

Aethlon Medical, Inc. (AEMD) Q4 2024 Earnings Call Transcript

Aethlon Medical Announces Financial Results for the Fiscal Year Ended March 31, 2024 and Provides Corporate Update

Jun 27, 2024, 4:15 PM EDT - 1 year ago

Aethlon Medical Announces Financial Results for the Fiscal Year Ended March 31, 2024 and Provides Corporate Update

Aethlon Medical to Release Fiscal Year End Financial Results and Host Conference Call on June 27, 2024

Jun 21, 2024, 8:01 AM EDT - 1 year ago

Aethlon Medical to Release Fiscal Year End Financial Results and Host Conference Call on June 27, 2024

What's Next in Treatments for Cancer Patients with Solid Tumors?

Jun 20, 2024, 7:00 AM EDT - 1 year ago

What's Next in Treatments for Cancer Patients with Solid Tumors?

Aethlon Medical Receives Ethics Committee Approval for Hemopurifier® Cancer Trial

Jun 18, 2024, 8:01 AM EDT - 1 year ago

Aethlon Medical Receives Ethics Committee Approval for Hemopurifier® Cancer Trial

The Hunt for Virus Treatments Continues Post Covid-19

Jun 7, 2024, 8:00 AM EDT - 1 year ago

The Hunt for Virus Treatments Continues Post Covid-19

Waffels
Waffels Jan. 28 at 4:39 PM
$AEMD this stock still very cute and one my favorite
0 · Reply
smoothest06
smoothest06 Jan. 27 at 2:20 PM
$AEMD
0 · Reply
ChartChartist
ChartChartist Jan. 25 at 7:50 PM
$AEMD im impatient
0 · Reply
echo_fable
echo_fable Jan. 24 at 2:48 PM
$AEMD 5$ by next week?
0 · Reply
echo_fable
echo_fable Jan. 24 at 2:47 PM
$AEMD
0 · Reply
smoothest06
smoothest06 Jan. 23 at 4:06 PM
$AEMD
0 · Reply
inapick
inapick Jan. 23 at 1:34 PM
$AEMD all this company has ever done is drain its investors of their funds through constant R/S's If i could i would
0 · Reply
TheRealSonic
TheRealSonic Jan. 16 at 11:18 PM
The Hedghog’s list for next week: $OCG $EVTV $AEMD $FRGT $BJDX
0 · Reply
shuffle13
shuffle13 Jan. 16 at 10:31 PM
$AEMD https://www.sec.gov/Archives/edgar/data/882291/000168316826000376/aethlon_424b3.htm
0 · Reply
smoothest06
smoothest06 Jan. 16 at 10:30 PM
$AEMD
0 · Reply
Kindom65
Kindom65 Jan. 16 at 10:28 PM
$AEMD
0 · Reply
luka1971
luka1971 Jan. 15 at 12:13 PM
$AEMD 👀
0 · Reply
walker7782
walker7782 Jan. 13 at 8:47 PM
$AEMD Painful - I'm out. Scaled out so I didn't dump on the ask. Had to lock 10% profits if I could on a day like today...good luck!
0 · Reply
walker7782
walker7782 Jan. 13 at 4:13 PM
$AEMD Still holding 2.39 average
0 · Reply
QuantumTechnology
QuantumTechnology Jan. 12 at 6:15 PM
$AEMD Has one more run in it before next R/S imo.
0 · Reply
ChartChartist
ChartChartist Jan. 10 at 11:49 PM
$NDRA like $SSM welp, pump it $AEMD sad its so good tho $BOXL 775k is good volume but $$$$$. $HWH $$$$$$$ dis is da one Top play next week
0 · Reply
UNCLE_SCROOGE_
UNCLE_SCROOGE_ Jan. 8 at 4:55 PM
$AEMD Oh, finally this scam company is about to go bankrupt. Thank God.☺️
0 · Reply
kellys2025
kellys2025 Jan. 7 at 8:49 PM
$AEMD Attached is a newly published peer-reviewed paper in BMJ Open outlining the scientific rationale and design of the Australian Clinical Trial of the Aethlon Hemopurifier in Oncology : https://bmjopen.bmj.com/content/16/1/e102581.full
0 · Reply
Waffels
Waffels Jan. 7 at 12:00 AM
$AEMD i always like this. my mom could use 5 hemopurifier right now
1 · Reply
OPTIONTURD
OPTIONTURD Dec. 31 at 8:30 PM
$AEMD They need to sell their great product to Hospitals, Doctors, ER'S, ETC. Hasn't it been a proven filter? Profits, more profits, and more profits and it could be a $50/share company. All this research money and investor's money is only paying for salaries and research. Get off the pot and go.
2 · Reply
GPSGlow
GPSGlow Dec. 27 at 5:24 PM
$AEMD Investors are weighing durability against tactical noise; commercial execution has to tighten in upcoming quarters — clear evidence of repeatability would change the narrative. Markets will follow data, not narratives.
0 · Reply
ChartChartist
ChartChartist Dec. 27 at 3:41 PM
$AEMD so ready
0 · Reply